CN116510062A - 一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法 - Google Patents
一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法 Download PDFInfo
- Publication number
- CN116510062A CN116510062A CN202310453886.4A CN202310453886A CN116510062A CN 116510062 A CN116510062 A CN 116510062A CN 202310453886 A CN202310453886 A CN 202310453886A CN 116510062 A CN116510062 A CN 116510062A
- Authority
- CN
- China
- Prior art keywords
- sponge
- nanocellulose
- preparation
- sea squirt
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251555 Tunicata Species 0.000 title claims abstract description 38
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 23
- 229920001690 polydopamine Polymers 0.000 claims abstract description 45
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 32
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 32
- 229920002752 Konjac Polymers 0.000 claims abstract description 32
- 229940046240 glucomannan Drugs 0.000 claims abstract description 32
- 235000010485 konjac Nutrition 0.000 claims abstract description 32
- 229920001046 Nanocellulose Polymers 0.000 claims abstract description 28
- 229920001661 Chitosan Polymers 0.000 claims abstract description 26
- 239000002105 nanoparticle Substances 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 229920002678 cellulose Polymers 0.000 claims abstract description 7
- 239000001913 cellulose Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 238000003756 stirring Methods 0.000 claims description 25
- 241000251557 Ascidiacea Species 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- 238000004061 bleaching Methods 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 241001312219 Amorphophallus konjac Species 0.000 claims description 4
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 4
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 239000000252 konjac Substances 0.000 claims description 4
- 239000012779 reinforcing material Substances 0.000 claims description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 238000010907 mechanical stirring Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 abstract description 4
- 229920001282 polysaccharide Polymers 0.000 abstract description 4
- 239000005017 polysaccharide Substances 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 4
- 230000023597 hemostasis Effects 0.000 abstract description 3
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000012620 biological material Substances 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000004298 light response Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 abstract 1
- 229960000977 trabectedin Drugs 0.000 abstract 1
- 102100022808 Kielin/chordin-like protein Human genes 0.000 description 62
- 239000000243 solution Substances 0.000 description 31
- 206010052428 Wound Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000000601 blood cell Anatomy 0.000 description 10
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 10
- 230000006835 compression Effects 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 125000003172 aldehyde group Chemical group 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000002262 Schiff base Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000004753 Schiff bases Chemical class 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- -1 ABTS free radical Chemical class 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001507 sample dispersion Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/16—Materials with shape-memory or superelastic properties
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于生物材料制备技术领域,具体涉及一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法。本发明以壳聚糖、氧化魔芋葡甘露聚糖为基质材料,以纳米海鞘纤维素与聚多巴胺纳米颗粒为主要增强原料,首先通过氧化法将魔芋葡甘露聚糖改性成为氧化魔芋葡甘露聚糖,构建的海鞘纳米纤维素/聚多巴胺多糖基支架材料,不仅具有良好的红外光响应抗菌效果,其均一的三维大孔结构使海绵支架能够实现快速止血的功能,且能够有效清除自由基,促进伤口处愈合。所制备的海绵生物相容性良好、无细胞毒性,有望成为一种新型的快速止血、有效抗菌支架材料。
Description
技术领域
本发明属于生物材料制备技术领域,具体涉及一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法。
背景技术
据统计,由战争、意外事故等引起的不可控出血及其并发症是造成死亡的重要原因,也是目前临床上面临的重要挑战。开放性伤口易受外部细菌感染,导致严重的炎症,抑制伤口愈合,甚至导致死亡。快速有效的新型多功能伤口敷料一直是医疗保健领域研究的热点。然而,目前市售伤口敷料大多价格昂贵,且存在止血效果不稳定、易引起炎症反应等缺点。因此,一种低成本、具有快速止血能力且抗菌性能优良的止血材料亟待开发。
魔芋葡甘露聚糖(KGM)是一种水溶性高分子多糖,具有较好的凝胶性、抗菌性以及免疫调节能力等多种特性。研究表明,将魔芋葡甘露聚糖氧化得到的氧化魔芋葡甘露聚糖(OKGM)可以通过席夫碱反应与壳聚糖(CS)进行交联,形成的OKGM-CS水凝胶相比于大多数伤口敷料更为安全、持久。但该材料缺乏抗菌性能,且机械强度较差,故其止血性能难以达到临床要求。
基于此,本发明提供一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法,以壳聚糖/氧化魔芋葡甘露聚糖为基底的止血海绵通过掺入海鞘纳米纤维素和聚多巴胺纳米粒子赋予了止血海绵优异的机械强度、黏附性能和光热抗菌性能,为构建理想的止血材料提供了新思路。
发明内容
本发明的目的在于提供一种快速止血、红外光响应的海鞘纳米纤维素/聚多巴胺多糖基止血海绵的制备方法,将魔芋葡甘露聚糖通过高碘酸钠氧化成为氧化魔芋葡甘露聚糖,改性后的醛基与壳聚糖中的氨基进行席夫碱反应,实现首次交联,海鞘纳米纤维素的加入显著提高了海绵的力学性能。聚多巴胺纳米颗粒引入后,其氨基可以与魔芋葡甘露聚糖的醛基反应实现第二次交联。聚多巴胺纳米颗粒不仅起到了交联剂的作用,同时为海绵带来良好的抗菌、抗氧化以及粘附性能。
氧化改性后的魔芋葡甘露聚糖与壳聚糖相交联,使海绵具有均一整齐的大孔结构,能够快速吸附血细胞,带来良好的凝血效果,海绵支架具有一定的压缩强度与形状记忆功能,充当止血剂时能够快速吸收大量血液,吸血膨胀的过程中可对创口产生压力,减少出血量;海绵中掺杂的聚多巴胺具有良好的光转热能力,呈现出优异的光热抗菌效果,可以有效避免过度使用和滥用抗生素造成的耐药菌的发展。同时聚多巴胺能够清除自由基,赋予海绵独特的抗氧化性能。该海绵具有良好的生物相容性,无细胞毒性与溶血现象,溶血率低,安全性高。
为实现上述目的,本发明采用如下技术方案:
一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法,以壳聚糖和氧化魔芋葡甘露聚糖为海绵的骨架材料,海鞘纳米纤维素为增强材料,将聚多巴胺纳米颗粒加入其中冷冻干燥后获得止血海绵。
所述的一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵的制备方法,具体包含以下步骤:
(1)聚多巴胺纳米颗粒的制备方法;
(2)氧化魔芋葡甘露聚糖的制备方法;
(3)海鞘纳米纤维素的制备方法;
(4)将不同含量的海鞘纳米纤维素加入去离子水中,超声至完全分散后加入壳聚糖与氧化魔芋葡甘露聚糖,搅拌形成均匀液后冷冻干燥得到初步的止血海绵,即KCT海绵,其中海鞘纳米纤维素的掺杂量分别为0wt % ~5wt %。通过力学测试,确定海鞘纳米纤维素掺杂的最优掺杂量为2wt %。
(5)将海鞘纳米纤维素分散液加入壳聚糖与氧化魔芋葡甘露聚糖中,搅拌均匀后,加入聚多巴胺纳米颗粒,搅拌6h,最后冷冻干燥得到最终的止血海绵,即KCP海绵,其中海鞘纳米纤维素的掺杂量为2wt %,聚多巴胺纳米颗粒的掺杂量为0.5 wt%~2 wt%。
进一步的,步骤(4)和(5)中壳聚糖与氧化魔芋葡甘露聚糖的质量比为9:1。
进一步的,所述聚多巴胺纳米颗粒的制备方法包括:将氨水、无水乙醇、去离子搅拌混合均匀,记为溶液A。然后将多巴胺溶解在适量去离子水中,记为溶液B。将溶液B逐滴加入到上述混合溶液A中。搅拌反应30h,离心后蒸馏水洗涤3次,60℃干燥,获得聚多巴胺纳米颗粒,即PDA NPs。
进一步的,氨水、无水乙醇、去离子的体积比为1:45:100,氨水浓度为25-28wt%。
进一步的,所述氧化魔芋葡甘露聚糖的制备方法包括以下步骤:将5.0g魔芋葡甘露聚糖加入500ml水中,搅拌得到均一的水分散体系后加入5.0g高碘酸钠,控制温度30℃,在黑暗环境中反应12h,然后加入适量的乙二醇继续反应2h以除去未反应的氧化剂,透析72h。离心后收集上清液,干燥后获得氧化魔芋葡甘露聚糖。
进一步的,所述海鞘纳米纤维素的制备方法包括以下步骤:
1)将海鞘清洗干净并去除内脏,保留外被囊;将海鞘外被囊背部的杂草剪除、并除去外被囊内侧附着的薄膜后用水洗净,放入烘箱烘干,用锤子将其敲碎,用粉碎机将其研磨成海鞘粉;
2)在5wt%的氢氧化钠溶液中加入海鞘粉水浴搅拌;重复碱泡步骤3-4次,以除去脂质层,并用水洗至中性;
3)将冰醋酸、次氯酸钠和蒸馏水配置成漂白液,将碱泡后得到的海鞘粉加入到漂白液中水浴搅拌,期间不断加入冰醋酸和次氯酸钠,直至漂白;
4)将漂白后的海鞘悬浊液抽滤,用水冲洗海鞘粉直至中性,然后烘干得到海鞘纤维素;
5)将烘干后的海鞘纤维素加入60wt%的硫酸溶液中,水浴机械搅拌,水解结束后加入大量冰蒸馏水终止反应后离心洗涤2次,去除上层酸液,收集底部沉淀后加入适量蒸馏水继续离心,收集上层悬液,蒸发浓缩,浓缩液用超声波粉碎机混合均匀后装入透析袋透析至中性,冻干得到海鞘纳米纤维素。
进一步的,步骤2)中水浴温度为40℃。
进一步的,步骤3)中水浴温度为60℃。
进一步的,步骤4)中烘干温度为60℃。
进一步的,步骤5)中水浴机械搅拌的温度为55℃,时间为2h。
壳聚糖具有丰富的氨基基团,可与醛基等形成化学交联,与邻苯二酚等物质形成强氢键,阳性氨基能够诱导血小板粘附和红细胞聚集,为壳聚糖带来优异的止血特性。因此以壳聚糖和氧化魔芋葡甘露聚糖为海绵的骨架材料,构成了均一整齐的大孔结构,后以海鞘纳米纤维素为增强材料,将聚多巴胺纳米颗粒加入其中冷冻干燥后获得能够快速止血、光热抗菌的海绵。
PDA NPs中含有大量的邻苯二酚,在不激发光热作用的条件下,也可以产生活性氧或通过静电效应在一定程度上破坏细菌胞壁及膜结构,达到抗菌作用。在激发光热作用条件下,PDA NPs可对红外光进行响应,其光转热能力赋予海绵优良的抗菌特性。
另外,PDA NPs中的儿茶酚基团可与血液中的三价铁离子具有很强的螯合作用,添加后赋予海绵聚集与浓缩血细胞的能力,使血细胞紧紧粘附包裹着海绵,促进凝血因子的激活与血栓的形成。同时儿茶酚基团可通过与组织中的基团形成化学键以提高界面粘附力,因此应用于止血材料中可以实现对伤口的密封效果。
本发明作为一种伤口敷料,具有良好的溶胀性能与生物相容性,对于伤口渗出液吸收程度较高,且有利于药物、营养物质以及氧气的运输,溶胀性能良好的敷料能够使伤口持续湿润,加速血液凝固。同时具有抗氧化活性,为伤口清除多余自由基,促进伤口愈合。
本发明的显著优点在于:
(1)本发明将魔芋葡甘露聚糖改性成为双醛葡甘聚糖,利用席夫碱反应与壳聚糖交联,形成了均一的三维网络结构,孔隙适中使海绵具有良好的血液吸收率,并有助于细胞在其上生长。
(2)本发明首次将海鞘纤维素加入多糖基体系中制成一种拥有良好机械性能的材料,既能防止因创口血流压力过高导致敷料破裂,残渣遗落在伤口附近,造成不利影响,又能具有韧性,避免硬度过高,加重患处疼痛感。纤维穿插的大孔结构,有助于截留血细胞,促进血细胞凝集,诱导血液凝固。
(3)本发明添加聚多巴胺纳米颗粒,其中的儿茶酚结构促进海绵与皮肤、肝脏表面细胞粘附,能够为海绵带来粘附性,实现对伤口的密封,确保了海绵在应用时不会出现创面脱位,能够达到类似于纱布等的填塞效果。同时本发明添加的聚多巴胺纳米颗粒具有独特的光转热能力,局部热疗导致热休克蛋白不可逆损伤,破坏细菌胞膜使内物质泄漏,威胁细菌正常生理活动从而达到抗菌效果。
(5)本发明制备的KCP海绵具有形状适应性,在狭小创面止血时,接触血液后,海绵产生力膨胀,膨胀的海绵能够对创口产生压力,减少出血量,类似于手动产生的一些按压压缩止血,也可以压迫伤口多余组织液渗出,同时提供湿润的环境,结合独特的粘附性能,可以很好地保护伤口,避免感染。
(6)本发明制备的KCP海绵生物相容性良好,无细胞毒性,且溶血率低。有着良好的抗氧化活性,清除伤口自由基,促进伤口愈合。
附图说明
图1为实施例1制得的KCT海绵力学性能曲线;
图2为实施例2制得的KCP海绵样品图;
图3为实施例2制得的KCP海绵微观电镜图;
图4为实施例2制得的KCP海绵力学性能测试结果图;
图5为实施例2制得的KCP海绵的傅立叶红外光谱图;
图6为实施例2制得的KCP海绵的XRD图谱;
图7为实施例2制得的KCP海绵的孔隙率;
图8为实施例例2制得的KCP海绵的吸血量;
图9为实施例2制得的KCP海绵的溶血率;
图10为实施例2制得的KCP海绵的抗氧化活性;
图11为实施例2制得的KCP海绵与大肠杆菌和金黄色葡萄球菌培养后菌液稀释后接种在平板上的菌落形成图;
图12为实施例2制得的KCP海绵红外光照射状态下杀菌率;
图13为实施例2制得的KCP海绵非红外光照射下杀菌率
图14为实施例2制得的KCP海绵血细胞粘附电镜图。
具体实施方式
为了使本发明所述的内容更加便于理解,下面结合具体实施方式对本发明所述的技术方案做进一步的说明,但是下述的实例仅仅是本发明其中的例子而已,并不代表本发明所限定的权利保护范围,本发明的权利保护范围以权利要求书为准。
实施例1 KCT海绵的制备
(1)将2g壳聚糖粉末加入100ml体积分数为1%的乙酸溶液中,于60℃恒温水浴锅中搅拌溶解,形成溶液A;
(2)取0.2g氧化魔芋葡甘露聚糖,加入50ml去离子水中,搅拌至完全溶解,形成溶液B;
(3)将90ml溶液A和10ml溶液B混合,搅拌形成均匀溶液,记为溶液C;
(4)取0.072g海鞘纳米纤维素,加入20ml去离子水中,超声至均匀分散后,加入溶液C中,搅拌至形成均匀溶液;
(5)将步骤(4)所得溶液注入模具,依次放置于4℃下1h、-20℃下4h和-80℃下12h,形成固体A;
(6)将步骤(5)中得到的固体A于真空冷冻干燥机中进行冷冻干燥,除去样品中的水分,48h后取出,最终得到TCNCs掺杂量为2wt%的复合海绵,编号KCT2。
实施例2 KCP海绵的制备
(1)将2g壳聚糖粉末加入100ml体积分数为1%的乙酸溶液中,于60℃恒温水浴锅中搅拌溶解,形成溶液A;
(2)取0.2g氧化魔芋葡甘露聚糖,加入50ml去离子水中,搅拌至完全溶解,形成溶液B;
(3)将90ml溶液A和10ml溶液B混合,搅拌形成均匀溶液,记为溶液C;
(4)取0.072g海鞘纳米纤维素,加入20ml去离子水中,超声至均匀分散后,加入溶液C中,搅拌至均匀,记为溶液D;
(5)将0.036g聚多巴胺纳米颗粒加入溶液D中,搅拌至均匀;
(6)将步骤(5)所得溶液注入模具,依次放置于4℃下1h、-20℃下4h和-80℃下12h,形成固体A;
(7)将步骤(6)中得到的固体A于真空冷冻干燥机中进行冷冻干燥,除去样品中的水分,48h后取出,最终得到海鞘纳米纤维素增强的壳聚糖/氧化魔芋葡甘露聚糖/聚多巴胺纳米颗粒海绵,其中,TCNCs掺杂量为2wt%,PDA NPs的掺杂量为1wt%,编号KCP1。
实施例3海绵支架材料性能测定
(1)机械强度
通过调整海鞘纳米纤维素的用量,其余操作同实施例1,使最终得到的KCT海绵中海鞘纳米纤维素的掺杂量分别为0%、1%、2%、3%、4%、5%,用压缩模量测试仪测定TCNCs掺杂量为0%-5%的KCT海绵材料的机械性能,将样品置于样品台,设置软件参数,以压缩速度0.5mm/min缓慢压缩,得到力-形变曲线。
结果:如图1所示,随着TCNCs含量的增加,KCT复合海绵最大承受力逐渐上升,因TCNCs提取时表面带负电荷,过多的TCNCs掺杂会和壳聚糖发生正负电荷絮凝现象,使KCP海绵脆性加剧,机械强度骤然下降。综合力学性能指标,本发明确定了以掺杂量为2wt%的TCNCs制备KCP复合海绵。
(2)扫描电镜(SEM)
通过调整聚多巴胺纳米颗粒的用量,其余操作同实施例2,使最终得到的KCP海绵中聚多巴胺纳米颗粒的掺杂量分别为0%、0.5%、1%、2%,将这4组KCP止血海绵样品切成薄片,将导电双面胶贴于载物台上,取棉签蘸少量样品于双面胶表面,样品依次处理,利用场发射扫描电子显微镜进行横截面形貌观察。
结果:如图3所示,用扫描电镜观察KCP各组的微观结构,发现KCP海绵形成了三维大孔网络结构,4种浓度的KCP海绵,孔径范围均在50-80μm范围内,说明未对孔径产生过多影响;同时通过倍数放大至10μm,可清晰地观察到多巴胺纳米颗粒附着在网状孔隙表面,根据掺杂浓度的不同,附着量依次变化,几组KCP海绵孔状结构相似;倍数放大至1μm,可观察到KCP海绵中的多种物质通过化学反应交联形成孔周,且支出丝状的纤维素触角,同时与聚多巴胺纳米颗粒发生反应,因此孔周与触角将聚多巴胺纳米颗粒包裹在内,形成紧密的结合交联结构。
(3)力学性能
将海绵浸泡在PBS中达到溶胀平衡状态,用手按压到最大形变,直观观察其压缩性能。并使用万能试验机(TPA,FTC,美国)来进一步测试海绵的压缩性能。在循环压缩测试模型中,以1mm/s的速度压缩至50%的变形量,然后以相同速度恢复至0%应变。每组设置3个平行样品,重复3次。
结果:如图4所示,无论是使用手指按压,或提升更大的外界压力(压力机),一旦消除应力,KCP海绵均可以快速恢复形态。当压缩达到50%时,四组相应的力分别为1.01N、0.86N、0.82N和0.81N。相较于KCP0,KCP0.5和KCP1、KCP2的相应的力有所下降,说明PDA NPs的邻苯二酚结构与壳聚糖中的氨基形成强氢键等反应增强了KCP复合海绵的柔韧性,改善了CS/OKGM海绵的脆性。上述结果证明该海棉具有良好的抗压能力与快速回弹性,可以更好地为伤口提供物理屏障。
(4)红外吸收光谱(FTIR)
将4组KCP止血海绵样品及OKGM、CS、PDA NPs、TCNCs原料样品处理后研磨成粉末,用溴化钾压片制样,用傅立叶变换红外光谱仪上进行测定。
结果:如图5所示,OKGM中1647 cm-1处醛基(C=OH)的吸收峰,证实了KGM成功被高碘酸钠氧化。KCP海绵中1610cm-1出现酰胺键增强峰的特征,可以推断出CS中氨基与OKGM中的醛基确发生席夫碱反应。
(5)X射线衍射(XRD)
将4组KCP止血海绵样品及OKGM、CS、PDA NPs原料样品处理后研磨成粉末,用X射线衍射仪上进行测定,用超能探测器记录2θ=5°~60°时材料的X-射线衍射强度曲线。
结果:如图6所示,通过对各组分以及KCP止血海绵进行XRD分析,OKGM与CS的特征峰消失,说明确实参与体系反应;同时在KCP图谱中16.4°以及22.6°处可以观察到海鞘纳米纤维素以及PDA NPs所对应的特征峰,表明二者已成功掺杂。
(6)孔隙率、血液吸收率
孔隙率采取乙醇浸泡法测试,血液吸收率采取全血吸收法测定,通过公式计算出孔隙率与血液吸收率。
结果:如图7所示,适当的PDA NPs添加并不会影响孔隙率,掺杂量的增加使海绵中的游离氨基量更多,醛基与氨基形成的席夫碱键使海绵中的结构更加致密,孔隙减少;如图8所示,KCP1海绵能够吸收自身重量3100%的血液质量,进一步证实KCP海绵大孔均一网状结构与良好的血细胞粘附能力有利于快速止血。
(7)溶血率、抗氧化活性
将0.5 mL浓度为5%的红细胞加入到不同浓度的0.5 mL KCP样品分散液中,经孵育离心过程后测量上清液的吸光度。去离子水和生理盐水分别作为阳性对照和阴性对照,利用公式算出溶血率。
KCP海绵的抗氧化活性是利用ABTS自由基试剂盒进行评估,后针对各组测定对应吸光度。利用公式计算抗氧化活性。
结果:如图9所示,各组KCP海绵溶血率均低于5%,以此证明KCP海绵具有很好的血液相容性;如图10所示,随着聚多巴胺掺杂量增加,自由基清除清除能力不断增强。
(8)杀菌率
将四组KCP海绵与菌液共培养12h,稀释后涂覆接种在平板上,直观的观察验证KCP海绵的抑菌效果;后通过测量相应OD值,计算杀菌率。
结果:如图11所示,聚多巴胺掺杂的情况下,板中细菌随着添加光照而显著减少;如图12,13所示,NIR光照组KCP0、KCP0.5、KCP1、KCP2细菌杀灭率达90%以上,对大肠杆菌的杀灭率分别为7.8%、95.6%、98.5%、98.6%;对金黄色葡萄球菌的杀灭率分别为12.4%、96.2%、98.1%和99.0%。 -NIR光照组KCP0、KCP0.5、KCP1、KCP2细菌杀灭率仅为15%左右,对大肠杆菌的杀灭率分别为7.1%、15.5%、15.0%、16.9%;对金黄色葡萄球菌的杀灭率分别为8.0%、14.0%、13.7%和15.1%,因此表现出KCP海绵有着良好的光热抗菌效果。
(9)血细胞粘附
将新鲜血液滴入四组KCP圆片上,37 °C孵育30分钟。接着用戊二醛固定红细胞2小时,然后依次用不同浓度的乙醇脱水。最后,通过SEM观察红细胞粘附。设置商用明胶海绵为对照组。
结果:如图14所示,通过SEM电镜观察吸血后的KCP系列海绵发现,KCP海绵能够有效促进血细胞吸附,粘附的血细胞数量远大于对照组所粘附的数量,说明KCP系列海绵可以通过富集红细胞和血小板达到凝血效果。综合以上结果,KCP海绵中聚多巴胺的最优掺杂量为1%。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (10)
1.一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵的制备方法,其特征在于:以壳聚糖和氧化魔芋葡甘露聚糖为海绵的骨架材料,海鞘纳米纤维素为增强材料,将聚多巴胺纳米颗粒加入其中冷冻干燥后获得止血海绵。
2.根据权利要求1所述的一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵的制备方法,其特征在于:具体包含以下步骤:
(1)聚多巴胺纳米颗粒的制备方法;
(2)氧化魔芋葡甘露聚糖的制备方法;
(3)海鞘纳米纤维素的制备方法;
(4)将海鞘纳米纤维素分散液加入壳聚糖与氧化魔芋葡甘露聚糖中,搅拌均匀后,加入聚多巴胺纳米颗粒,搅拌6h,最后冷冻干燥得到所述止血海绵,即KCP海绵。
3.根据权利要求2所述的制备方法,其特征在于,步骤(4)中壳聚糖与氧化魔芋葡甘露聚糖的质量比为9:1。
4. 根据权利要求2所述的制备方法,其特征在于,所述止血海绵中海鞘纳米纤维素的掺杂量为2wt%,聚多巴胺纳米颗粒的掺杂量为0.5wt%~2 wt%。
5.根据权利要求2所述的制备方法,其特征在于,所述聚多巴胺纳米颗粒的制备方法包括:将氨水、无水乙醇、去离子搅拌混合均匀,记为溶液A;然后将多巴胺溶解在适量去离子水中,记为溶液B;将溶液B逐滴加入到溶液A中,搅拌反应30h,离心后蒸馏水洗涤3次,60℃干燥,获得聚多巴胺纳米颗粒,即PDA NPs。
6.根据权利要求5所述的制备方法,其特征在于,氨水、无水乙醇、去离子的体积比为1:45:100,氨水浓度为25-28wt%。
7.根据权利要求2所述的制备方法,其特征在于,所述氧化魔芋葡甘露聚糖的制备方法包括:将5.0g魔芋葡甘露聚糖加入500ml水中,搅拌得到均一的水分散体系后加入5.0g高碘酸钠,控制温度30℃,在黑暗环境中反应12h,然后加入适量的乙二醇继续反应2h以除去未反应的氧化剂,透析72h,离心后收集上清液,恒温干燥后获得氧化魔芋葡甘露聚糖。
8.根据权利要求2所述的制备方法,其特征在于,所述海鞘纳米纤维素的制备方法包括以下步骤:
1)将海鞘清洗干净并去除内脏,保留外被囊;将海鞘外被囊背部的杂草剪除、并除去外被囊内侧附着的薄膜后用水洗净,放入烘箱烘干,用锤子将其敲碎,用粉碎机研磨成海鞘粉;
2)在5wt%的氢氧化钠溶液中加入海鞘粉水浴搅拌;重复碱泡步骤3-4次,以除去脂质层,并用水洗至中性;
3)将冰醋酸、次氯酸钠和蒸馏水配置成漂白液,将碱泡后的海鞘粉加入到漂白液中水浴搅拌,期间不断加入冰醋酸和次氯酸钠,直至漂白;
4)将漂白后的海鞘悬浊液抽滤,用水冲洗海鞘粉直至中性,然后烘干得到海鞘纤维素;
5)将烘干后的海鞘纤维素加入60wt%的硫酸溶液中,水浴机械搅拌,水解结束后加入大量冰蒸馏水终止反应后离心洗涤2次,去除上层酸液,收集底部沉淀后加入适量蒸馏水继续离心,收集上层悬液,蒸发浓缩,浓缩液用超声波粉碎机混合均匀后装入透析袋透析至中性,冻干得到海鞘纳米纤维素。
9.根据权利要求8所述的制备方法,其特征在于,步骤2)中水浴温度为40℃;步骤3)中水浴温度为60℃;步骤4)中烘干温度为60℃;步骤5)中水浴机械搅拌的温度为55℃,时间为2h。
10.根据权利要求1-9任一项所述的制备方法制得的海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310453886.4A CN116510062A (zh) | 2023-04-25 | 2023-04-25 | 一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310453886.4A CN116510062A (zh) | 2023-04-25 | 2023-04-25 | 一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116510062A true CN116510062A (zh) | 2023-08-01 |
Family
ID=87396966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310453886.4A Pending CN116510062A (zh) | 2023-04-25 | 2023-04-25 | 一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116510062A (zh) |
-
2023
- 2023-04-25 CN CN202310453886.4A patent/CN116510062A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Biomimetic lignin/poly (ionic liquids) composite hydrogel dressing with excellent mechanical strength, self-healing properties, and reusability | |
CN112300420B (zh) | 一种可注射抗菌互穿双网络水凝胶及其制备方法和应用 | |
CN111662464B (zh) | 一种壳聚糖/海藻酸钠双网络水凝胶的制备方法 | |
CN108853570B (zh) | 一种止血海绵及其制备方法 | |
CN104548187B (zh) | 一种改性海藻酸与明胶共混海绵及制备方法和应用 | |
CN111558081B (zh) | 一种制备单宁酸改性双层水凝胶的方法 | |
CN113817181B (zh) | 一种碳量子点修饰的双网络水凝胶及其制备方法 | |
CN113908328B (zh) | 一种基于海藻酸钠、纳晶纤维素的抗菌止血多孔微球 | |
CN112587717A (zh) | 一种金属阳离子交联海藻酸盐/细菌纤维素复合水凝胶抗菌敷料 | |
CN110152055A (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
WO2013028214A1 (en) | Antimicrobial hydrogel wound dressing | |
CN112791223B (zh) | 一种抗菌壳聚糖基止血贴 | |
CN113861452A (zh) | 一种导电抗菌复合水凝胶及其制备方法、应用 | |
Han et al. | Multifunctional hemostatic polysaccharide-based sponge enhanced by tunicate cellulose: A promising approach for photothermal antibacterial activity and accelerated wound healing | |
CN116510062A (zh) | 一种海鞘纳米纤维素增强的具有光热抗菌作用的快速止血海绵及其制备方法 | |
CN115850733B (zh) | 一种可注射用纳米粘土水凝胶及其制备方法和应用 | |
CN111184906A (zh) | 一种基于pva的液体敷料及其制备方法 | |
CN113209365B (zh) | 一种多功能封闭止血伤口敷料及其制备方法 | |
WO2010067378A2 (en) | Hydrogel composition | |
CN113058067B (zh) | 一种卤胺改性黄原胶/壳聚糖复合抗菌敷料及其制备方法 | |
CN113512132A (zh) | 一种快速止血水凝胶及其制备方法 | |
CN112057667A (zh) | 一种可降解吸收的生物止血材料 | |
TWI792730B (zh) | 綠梔子素交聯聚乙烯醇/明膠/竹炭奈米顆粒複合材料及其製備方法 | |
AU2021104823A4 (en) | Method for preparing bacterial cellulose-based antibacterial material | |
CN113975455B (zh) | 一种可吸收止血粉和制备方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |